Inactive Instrument

RESP HEAL

Equities

RAP

AU000000RAP5

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Pfizer Australia Holdings Pty Limited completed the acquisition of ResApp Health Limited. CI
ResApp Health Secures Shareholder Approval for Takeover Scheme MT
ResApp Health Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
ResApp Health Limited Auditor Raises 'Going Concern' Doubt CI
ResApp Health Validates Effectivity of Respiratory Diagnostic App in Mask-Wearing Patients; Shares Fall 4% MT
ResApp Health Secures Court Orders for Scheme Deal MT
ResApp Health Agrees to One-Year Extension of Commercial License Deal MT
ResApp Health Limited Agrees to 12 Month Extension to its Commercial Licence Agreement with Medgate AG CI
ResApp Health Secures US FDA Medical Device Clearance for Sleep Apnea Software MT
ResApp Health Limited Receives FDA 510(K) Clearance for Sleepcheckrx CI
ResApp Health Gets Australian, Japanese Patents for Cough Detection Technology MT
ResApp Health Limited Announces Results from Data Confirmation Study CI
Pfizer Sweetens Offer to Acquire Australian ResApp Health MT
Transcript : ResApp Health Limited, Q3 2022 Earnings Call, Apr 26, 2022
ResApp Has Entered into A Research & Development Licence Agreement with Pfizer CI
Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited for approximately AUD 100 million. CI
Transcript : ResApp Health Limited - Special Call
ResApp Health Signs Deal for Pilot Testing of Respiratory Diagnostic App in the UK MT
ResApp Health Limited Signs One Year Agreement with the Dartford and Gravesham National Health Service CI
ResApp Health's Cough-based Diagnostic Test Achieves 92% Sensitivity Rate for COVID-19 Detection in Trial MT
Transcript : ResApp Health Limited - Special Call
ResApp Health Limited Announces Positive Results of Covid-19 Screening Test CI
ResApp Health Limited Reports Earnings Results for the Half Year Ended December 31, 2021 CI
Resapp Health, Health Teams to Launch ResAppDx on Aged Care Telehealth Platform MT
Health Teams to Launch ResAppDx on Aged Care Platform CI
Chart RESP HEAL
More charts
ResApp Health Limited is an Australia-based digital health company engaged in developing smartphone applications for the diagnosis and management of respiratory disease. The Company provides point of care diagnostic solutions for telehealth that are integrated into existing platforms. The Company is focused on developing apps to provide instant clinical diagnostic tests and management tools directly to consumers and healthcare providers. The Company's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. Its products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Its obstructive sleep aponia screening test uses overnight breathing and snoring sounds recorded on a smartphone.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock RESP HEAL - Australian S.E.
  4. News RESP HEAL
  5. ResApp Health : Gets Regulatory Nod for R&D Rebate; Shares Fall 6%